Home > Insider Trading > Filing (0001209191-15-043025)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1339970	Atyr Pharma Inc	LIFE	Biological Products, (No Disgnostic Substances) (2836)	203435077

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1202793	Michael Powell	C/O Sofinnova Ventures, Inc., 3000 Sand Hill Road, Bldg 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1245624	James Healy	C/O Sofinnova Ventures, Inc., 3000 Sand Hill Road, Bldg 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1590102	Anand Mehra	C/O Sofinnova Ventures, Inc., 3000 Sand Hill Road, Bldg 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1612133	Sofinnova Venture Partners Ix, L.p.	C/O Sofinnova Ventures, Inc., 3000 Sand Hill Road, Bldg 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1612134	Sofinnova Management Ix, L.l.c.	C/O Sofinnova Ventures, Inc., 3000 Sand Hill Road, Bldg 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-05-12	1,546,126	$0.00	1,546,126	No	4	C	Direct
Common Stock	Acquisiton	2015-05-12	320,000	$14.00	1,866,126	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series E Redeemable Convertible Preferred Stock	Disposition	2015-05-12	14,968,722	$0.00	1,546,126	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Person converted into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares converted into Common Stock on a 1-for-9.6814 basis.
Reflects a 1-for 9.6814 stock conversion of the Issuer's Preferred Stock into Common Stock which became effective immediately prior to the closing of the Issuer's initial public offering.
The shares are owned by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., Dr. Srinivas Akkaraju, and Dr. Anand Mehra are managing members of SM IX and exercise shared voting and investment power with respect to the shares owned by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.